is supported by a Presidents PhD Scholarship from Imperial College London, and A.I.O
Retatrutide is an investigational once-weekly triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from approved agents such as semaglutide and tirzepatide
[7] [8] Readers should check the current NICE Technology Appraisal for tirzepatide in weight management and the emc SmPC (medicines.org.uk) for the most up-to-date information on its licensed indications and eligibility criteria in the UK, as guidance may be updated
While these outcomes are impressive, it is important to remember that clinical trial averages do not guarantee individual results
Learn More About Dr
The winner will depend on Phase 3 data, tolerability, approval timing, label breadth, payer access, and real-world persistence